Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | LOX | P28300 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.32 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
| ▸ | DRD4 | P21917 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.31 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.30 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30768024 | 1.00 | NOTUM (0.36) | NOTUMMAOAMAOBLOXPARP1 | |
| SCHEMBL30288080 | 0.87 | UHRF1 (0.35) | MAOAMAOBLOXPARP1 | |
| SCHEMBL24011589 | 0.87 | UHRF1 (0.35) | MAOAMAOBLOXPARP1 | |
| SCHEMBL1405476 | 0.81 | NOTUM (0.50) | NOTUMPARP1PARP10DRD2DRD4 | |
| SCHEMBL24713940 | 0.81 | NOTUM (0.33) | NOTUMPARP1PARP10CDK2 | |
| SCHEMBL23384792 | 0.81 | UHRF1 (0.34) | NOTUMPARP1PARP10CDK2NISCH | |
| SCHEMBL26431777 | 0.81 | ALDH1A1 (0.34) | NOTUMPARP1PARP10CDK2 | |
| SCHEMBL24304266 | 0.78 | NOTUM (0.34) | NOTUMPARP1PARP10DRD2DRD4 | |
| SCHEMBL31161777 | 0.77 | ERN1 (0.39) | NOTUMMAOAMAOBLOXPARP1 | |
| SCHEMBL23977600 | 0.77 | GFER (0.32) | NOTUMPARP1PARP10DRD2DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388571-A1 | AMP-ACTIVATED PROTEIN KINASE MODULATOR COMPOUNDS AND USES THEREOF | BIOLEXIS THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-20250382285-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | C4 THERAPEUTICS, INC. (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250368631-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | C4 THERAPEUTICS, INC. (US) | 2025-12-04 | — | — | US | disclosed |
| EP-4638442-A1 | TRANSIENT RECEPTOR POTENTIAL VANILLOID 6 INHIBITORS | Uniquest Pty Limited (AU) | 2025-10-29 | — | — | EP | disclosed |
| US-12421220-B2 | Bicyclic-substituted glutarimide cereblon binders | C4 THERAPEUTICS, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-20250122179-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | C4 THERAPEUTICS, INC. (US) | 2025-04-17 | — | — | US | disclosed |
| EP-4536656-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | C4 Therapeutics, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| WO-2024201248-A1 | COMPOUNDS AND METHODS FOR DEGRADING GSPT1 | PIN THERAPEUTICS, INC. (KR) | 2024-10-03 | — | — | WO | disclosed |
| WO-2024130342-A1 | TRANSIENT RECEPTOR POTENTIAL VANILLOID 6 INHIBITORS | UNIQUEST PTY LIMITED (AU) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024130342-A1 | TRANSIENT RECEPTOR POTENTIAL VANILLOID 6 INHIBITORS | UNIQUEST PTY LIMITED (AU) | 2024-06-27 | — | — | WO | disclosed |
| EP-2049557-B1 | 1- (-D-GLYCOPYRANOSYL) - 3 - (4-CYCLOPROPYLPHENYLMETHYL) - 4 - HALOGENO INDOLE DERIVATIVES AND USE THEREOF AS SGLT INHIBITORS. | MITSUBISHI TANABE PHARMA CORP (JP) | 2011-03-09 | — | — | EP | disclosed |
| US-7851617-B2 | Indole derivatives | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-12-14 | — | — | US | disclosed |
| CN-101501053-A | 1- (-D-glucopyranosyl) -3- (4-cyclopropylphenylmethyl) -4-haloindole derivatives and their use as SGLT inhibitors | MITSUBISHI TANABE PHARMA CORP (JP) | 2009-08-05 | — | — | CN | disclosed |
| US-20080027122-A1 | Indole derivatives | TANABE SEIYAKU CO., LTD. | 2008-01-31 | — | — | US | disclosed |
| EP-0807631-B1 | Tricyclic compounds having fungicidal activity, their preparation and their use | SANKYO CO (JP) | 2003-03-12 | — | — | EP | disclosed |
| CN-1059904-C | Tricyclic compounds having fungicidal activity, their preparation and their use | SANKYO CO (JP) | 2000-12-27 | — | — | CN | disclosed |
| US-5981752-A | Tricyclic compounds having fungicidal activity, their preparation and their use | SANKYO COMPANY, LIMITED (JP) | 1999-11-09 | — | — | US | disclosed |
| US-5773618-A | PYRROLOQUINOLINONE DERIVATIVES | SANKYO COMPANY, LIMITED (JP) | 1998-06-30 | — | — | US | disclosed |
| CN-1172809-A | Tricyclic compounds having fungicidal activity, their preparation and their use | SANKYO CO (JP) | 1998-02-11 | — | — | CN | disclosed |
| EP-0807631-A1 | Tricyclic compounds having fungicidal activity, their preparation and their use | SANKYO COMPANY LIMITED (JP) | 1997-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250368631-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | CRBN, STUB1, CUL1 | NOTUM 2193/4885MAOA 3187/4885MAOB 3385/4885 |
| US-20080027122-A1 | Indole derivatives | SLC5A1, SLC5A2, SLC5A11 | NOTUM 3579/4885MAOA 654/4885MAOB 550/4885 |
| US-20250122179-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | CRBN, STUB1, CUL1 | NOTUM 2193/4885MAOA 3187/4885MAOB 3385/4885 |
| US-20250388571-A1 | AMP-ACTIVATED PROTEIN KINASE MODULATOR COMPOUNDS AND USES THEREOF | PRKAB2, PRKAB1, PRKAR2B | NOTUM 4364/4885MAOA 4000/4885MAOB 4077/4885 |
| US-20250382285-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | CRBN, STUB1, CUL1 | NOTUM 2193/4885MAOA 3187/4885MAOB 3385/4885 |
| US-12421220-B2 | Bicyclic-substituted glutarimide cereblon binders | CRBN, STUB1, CUL1 | NOTUM 2193/4885MAOA 3187/4885MAOB 3385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.